1. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review 
Prof Louisa Degenhardt, PhD, Amy Peacock, PhD, Samantha Colledge, BPsychSc[Hons], Janni Leung, PhD, Jason Grebely, PhD, Prof Peter Vickerman, PhD, Jack Stone, MMathStat, Evan B Cunningham, BSc[Hons], Adam Trickey, MSc, Kostyantyn Dumchev, MD, Prof Michael Lynskey, PhD, Paul Griffiths, MSc, Prof Richard P Mattick, PhD, Prof Matthew Hickman, PhD, Sarah Larney, PhD 
The Lancet Global Health 
Volume 5, Issue 12, Pages e1192-e1207 (December 2017)
DOI: /S X(17)
Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license Terms and Conditions

2. Figure 1
Flowchart presenting number of sources from identification to inclusion
UNODC WDR=UN Office on Drugs and Crime's World Drug Report. GSHR=HRI's Global State of Harm Reduction. EMCDDA=European Monitoring Centre on Drugs and Drug Addiction. HBV=hepatitis B virus. HCV=hepatitis C virus. IDU=injecting drug use.
The Lancet Global Health 2017 5, e1192-e1207DOI: ( /S X(17) )
Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license Terms and Conditions

3. Figure 2 Estimated prevalence of injecting drug use by country
IDU=injecting drug use.
The Lancet Global Health 2017 5, e1192-e1207DOI: ( /S X(17) )
Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license Terms and Conditions

4. Figure 3
Estimated HIV prevalence among people who inject drugs by country
IDU=injecting drug use. No eligible report=evidence of IDU located, but no study of HIV prevalence among people who inject drugs that met our eligibility criteria was located.
The Lancet Global Health 2017 5, e1192-e1207DOI: ( /S X(17) )
Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license Terms and Conditions

5. Figure 4
Estimated anti-hepatitis C virus prevalence among people who inject drugs by country
IDU=injecting drug use. No eligible report=evidence of IDU located, but no study of HCV antibody prevalence among people who inject drugs that met our eligibility criteria was located.
The Lancet Global Health 2017 5, e1192-e1207DOI: ( /S X(17) )
Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license Terms and Conditions

6. Figure 5
Estimated hepatitis B virus surface antigen prevalence among people who inject drugs by country
IDU=injecting drug use. No eligible report=evidence of IDU located, but no study of hepatitis B surface antigen prevalence among people who inject drugs that met our eligibility criteria was located.
The Lancet Global Health 2017 5, e1192-e1207DOI: ( /S X(17) )
Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license Terms and Conditions